People with longstanding type 2 diabetes often have more advanced beta cell dysfunction and may respond less robustly to GLP-1 therapy
"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment." New England Journal of Medicine , 2025 (ATTAIN-1 trial) Eli Lilly press release: ATTAIN-2 Phase 3 topline results
While initial progress may seem promising, weight loss plateaus eventually set in due to metabolic adaptations and a natural decline in resting energy expenditure
The liquid pharmaceutical composition according to any of the previous embodiments, wherein an improved chemical stability of the composition is obtained
Inject slowly over 2 3 seconds
Another natural compound, trigonelline, a methylated form of nicotinic acid, is a newly discovered NAD + precursor able to increase NAD + in multiple species, with preclinical implications for use in sarcopenia, and for muscle and cognitive decline in aging 124,130,131